We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Watson Pharmaceuticals and Sun Pharmaceutical Industries have entered into settlement agreements with Novartis that ends litigation involving their abbreviated new drug applications (ANDAs) seeking approval to market generic Exelon capsules.